Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder

NCT07523633 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help reduce cannabis use in adults who struggle with cannabis use disorder.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 100 people Planned (estimated).

Who can join Ages 18–70 · all sexes

Timeline Started 2026-04 · est. completion 2028-04

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT07523633 ↗

Description as written by the study sponsor.

The HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo. The first 50 participants will have functional brain scans (fMRI) to investigate how the brain responds to cannabis-related cues. The main outcome after 20 weeks is whether semaglutide reduces cannabis use compared to placebo. Changes in brain activity in response to cannabis cues will be explored as a secondary outcome.

Treatments tested

semaglutide Drug

semaglutide (Wegovy) once-weekly by subcutaneous injection, titrated to a maximum dose of 2.4 mg.
Placebo Drug

once-weekly by subcutaneous injection of saline (BD Posiflush)

Main thing measured	Cannabis consumption
Sponsor	Anders Fink-Jensen, MD, DMSci
Conditions studied	Cannabis Use Disorder, Cannabis Use Disorders, Cannabis Abuse, Cannabis Dependence, Cannabis Addiction
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07523633 ↗